Skip to main content
OpenTrials
Completed

NCT Number: NCT03750721

Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone and Joint Infection Antibiotic Resistant Staphylococcus Aureus Infection

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospices Civils de Lyon

Lyon, 69004, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients having had acute PJI (i.e. <1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)

Exclusion criteria

None

Treatment and study plan

Role of rifampin in staphylococcal PJI

Other

the aim is to determine if the dose and the duration of rifampin influenced the prognosis

Primary outcomes

  1. description of the use of rifampicin : rate of use

    Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

    the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR

Secondary outcomes

  1. rate of failure for treatment using rifampin

    Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

    Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

  2. rate of adverse event with rifampin

    Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

    Description of adverses events leading to stop the rifampicin

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Staphylococcal Acute Post-Operative Prosthetic Joint Infection Treated With 'DAIR' (Debridement and Implant Retention) And Impact Of Rifampin: A Retrospective Cohort Study In France

Acronym: IPASTAPH

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Nov 23, 2018
Registry last updated
Nov 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.